48results about How to "Reverses effect" patented technology

An optical communication system having an optical transmitter and an optical receiver optically coupled via a multi-path fiber. The optical transmitter launches, into the multi-path fiber, an optical transverse-mode-multiplexed (TMM) signal having a plurality of independently modulated components by coupling each independently modulated component into a respective transverse mode of the multi-path fiber. The TMM signal undergoes inter-mode mixing in the multi-path fiber before being received by the optical receiver. The optical receiver processes the received TMM signal to reverse the effects of inter-mode mixing and recover the data carried by each of the independently modulated components.

A health supplement consisting of numerous ingredients from several general groups including: anti-aging, anti-oxidant, vitamins, minerals, and elemental substances including metals. The supplement is specifically formulated for maximizing synergistic interaction of the ingredients while eliminating harmful interaction among the ingredients. A holistic approach to health is followed with ingredients to aid all systems of the human body. By addressing all human body systems, the supplement acts as a precursor to anti-aging and, when body systems are detoxified and oxidation is controlled, the effect of aging may be reversed.

The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention provides compositions and methods for treating disorders using combinations of drugs such as topiramate, ondansetron, and naltrexone.

A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing graft rejection, fetal loss, autoimmune disease, allergies and in inducing tumor cell growth.

A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

An apparatus for reversing inhaled anesthesia includes a filter for removing one or more anesthetic agents from gases passing therethrough, as well as a component for elevating CO2 levels in gases that are to be inhaled by a subject. The CO2 level-elevating component facilitates an increase in the ventilation of the subject without resulting in a significant decrease in the subject's PaCO2 level and, thus, a decrease in the rate at which blood flows through the subject's brain. A method of reversing the effects of inhaled anesthesia includes increasing the rate of ventilation of an anesthetized subject while causing the subject to inhale gases with elevated amounts of CO2 and while filtering anesthetic agents from such gases.

The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.

Two computer systems in a network each have a local store that contains a copy of a data item that is to be synchronized. One of the computer systems may be, for example, a mobile device while the other may be a synchronization server. In order to determine whether to synchronize a data item, and what synchronization mechanism to use, one of the computer systems references a flexible set of rules that may be influenced by instructions from a network administrator or a mobile device user. The flexible set of rules takes into consideration the value of the data, the cost associated with synchronization, the security of the synchronization mechanisms, the security of the mobile device, as well as the location of the mobile user in dictating whether and how to synchronize.

The present invention provides compositions and methods for protecting tissues and organs from damage during transplantation or from acute ischemia due to, e.g., injury or surgery. The compositions protect the tissue or organ from acidosis, oxidative damage, ischemia and repurfusion injury while the organ is isolated from the normal circulation or receives inadequate arterial flow.

A dietary supplement for removing or preventing the bio-accumulation of heavy metals in the body includes one or more chelators, precursors therefore, with at least one chelator capable of crossing the blood brain barrier to capture a heavy metal ion from a site in the central nervous system, and a vascular system promoter for assisting in distributing the chelators within the body. The chelator then crosses back through the blood brain barrier with the entrained heavy metal ion. Preferably, one or more secondary chelators bind any of the heavy metal released from the primary chelator and hold it for removal via an excretion pathway. In one embodiment, the supplement includes as glutathione or metallothionine assist in moving the chelated heavy metal out into the excretion pathway. Using the dietary supplement limits the accumulation of heavy metals in the body, promotes removal of heavy metals previously accumulated in the body and thereby alleviates the symptoms and conditions associated with heavy metal toxicity.

Nutritional compositions and methods of using the compositions for reducing the likelihood of the occurrence of and / or ameliorating the symptoms of heart disease. The compositions include proteins, phospholipids, vitamins and minerals and other nutritional ingredients. The compositions can be administered on a regular basis to promote good health and treat heart disease, including atherosclerosis.

A dietary supplement, preferably formulated with a confectionery base, removes or prevents the bio-accumulation of heavy metals in the body. The supplement has one or more natural chelators, or precursors therefore, with at least one chelator capable of crossing the blood brain barrier to capture a heavy metal ion from a site in the central nervous system. The chelator then crosses back through the blood brain barrier with the entrained heavy metal ion. Preferably, one or more secondary chelators bind any of the heavy metal released from the primary chelator and hold it for removal via an excretion pathway. In one embodiment, the supplement includes glutathione or metallothionine to assist in moving the chelated heavy metal out into the excretion pathway. Using the dietary supplement limits the accumulation of heavy metals in the body, promotes removal of heavy metals previously accumulated in the body and thereby alleviates the symptoms and conditions associated with heavy metal toxicity.

The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.

The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose of 2 μg to 60 μg, wherein said PTH peptide analogue has a reduced phospholipase-C activity and maintains adenylate cyclase activity.

A dietary supplement for removing or preventing the bio-accumulation of heavy metals in the body includes one or more chelators, precursors therefore, with at least one chelator capable of crossing the blood brain barrier to promote capture of a heavy metal ion from a site in the central nervous system, and a vascular system promoter for assisting in distributing the chelators within the body. The chelator then crosses back through the blood brain barrier with the entrained heavy metal ion. Preferably, one or more secondary chelators promotes binding any of the heavy metal released from the primary chelator and hold it for removal via an excretion pathway. In one embodiment, the supplement includes a cilantro extract to assist the body's' natural defense systems in removing mercury from the human body. Using the dietary supplement limits the accumulation of heavy metals in the body, which are encountered in trace amounts from various environmental sources, promotes removal of heavy metals previously accumulated in the body and thereby alleviates the symptoms and conditions associated with heavy metal toxicity.

The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.

Two computer systems in a network each have a local store that contains a copy of a data item that is to be synchronized. One of the computer systems may be, for example, a mobile device while the other may be a synchronization server. In order to determine whether to synchronize a data item, and what synchronization mechanism to use, one of the computer systems references a flexible set of rules that may be influenced by instructions from a network administrator or a mobile device user. The flexible set of rules takes into consideration the value of the data, the cost associated with synchronization, the security of the synchronization mechanisms, the security of the mobile device, as well as the location of the mobile user in dictating whether and how to synchronize.

The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.

An apparatus for reversing inhaled anesthesia includes a filter for removing one or more anesthetic agents from gases passing therethrough, as well as a component for elevating CO2 levels in gases that are to be inhaled by a subject. The CO2 level-elevating component facilitates an increase in the ventilation of the subject without resulting in a significant decrease in the subject's PaCO2 level and, thus, a decrease in the rate at which blood flows through the subject's brain. A method of reversing the effects of inhaled anesthesia includes increasing the rate of ventilation of an anesthetized subject while causing the subject to inhale gases with elevated amounts of CO2 and while filtering anesthetic agents from such gases.

A dietary supplement for removing or preventing the bio-accumulation of heavy metals in the body includes a primary chelator, a secondary chelator, and optionally a tertiary chelator or a precursor of a tertiary chelator. The primary chelator preferably crosses the blood brain barrier to capture a heavy metal ion from a site in the central nervous system. The primary chelator then crosses back through the blood brain barrier with the entrained heavy metal ion. The secondary chelator binds the heavy metal from or with the primary chelator for removal. In one embodiment, a tertiary chelator such as glutathione or metallothionine assists in moving the chelated heavy metal out into an excretion pathway. Using the dietary supplement limits the accumulation of heavy metals in the body, promotes removal of heavy metals previously accumulated in the body and alleviates the symptoms and conditions associated with heavy metal toxicity.

A system and method for engineering loss in a physical system by steering parameters of the physical system to the vicinity of an exceptional point is disclosed. In the vicinity of an exceptional point, localization of the fields helps to enhance any linear or nonlinear processes. As examples loss-induced transparency in the intracavity field intensities of coupled resonators, loss-induced suppression and enhancement of thermal nonlinearity in coupled resonators and loss-induced suppression and revival of Raman lasing in whispering-gallery-microcavities are demonstrated.

The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.

A protocol for use of growth factors to stimulate neuronal cell growth and activity in trkB receptor containing cortical tissues, including the entorhinal and hippocampal cortices. The method introduces exogenous growth factor, such as BDNF, NT-4 / 5 and NT-3, into the EC. The method is useful in therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease or for normal aging.

The present invention relates to novel analogs of choline and methods of use or treatment of neurodegenerative disorders and / or conditions such as Parkinson's disease, Huntington disease, Alzheimer's disease and related disorders such as amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease (mad cow disease), dementia with Lewy bodies, schizophrenia, paraneoplastic cerebellar degeneration and neurodegenerative conditions caused by stroke. The present compounds are effective to treat any neurological condition where acetylcholine transmission neurons and their target cells are affected. Compounds according to the present invention are effective to alleviate and / or reverse the effects of a neurodegenerative condition, prevent further deterioration and / or enhance cognition and memory in patients suffering from neurodegenerative disorders, especially Alzheimer's disease.

A method for recovering and extracting lithium from a feed liquid that may have a mixture of lithium and non-lithium salts present in the feed liquid. Salts of varying solubility are precipitated out of the feed liquid using water evaporation or other techniques. Pure lithium hydroxide is obtained using electrolysis or electro-dialysis processes in combination with a lithium ion selective inorganic membrane such as LiSICON. The negative effect of sodium and potassium on the lithium ion selective inorganic membrane is reduced by reversing the polarity of the current placed across the membrane.

Described herein are systems and methods for soft tissue reconstruction and augmentation using a platelet-rich fibrin matrix. In one embodiment the system of the present invention includes a blood collection apparatus capable of drawing blood from a patient, a matrix preparation container configured to hold a patient's blood while the blood is separated and coagulated to form a platelet-rich fibrin matrix therein, and a matrix delivery device configured to receive the matrix preparation container therein and compress and force the platelet-rich fibrin matrix out of the matrix preparation container and into the patient. In another embodiment the invention described herein is a method in which blood is drawn from a patient and separated and coagulated to form a platelet-rich fibrin matrix. The platelet-rich fibrin matrix is implanted into a patient at the site of a tissue defect or where tissue augmentation is desired.

A probabilistic prediction based artificial intelligence planning system comprises at least one processing unit capable of executing a set of instructions for a probabilistic prediction and modeling system; an input means for providing an input in communication with the processing unit; an output means for providing an output in communication with the processing unit; and an evaluation function for providing a score. The score is sent to the input means. A best output function provides a best output value to the processor based on probabilistic prediction values communicated from the probabilistic prediction and modeling system. Inputs and outputs are treated exactly the same within the probabilistic prediction and modeling system. Hypothetical outputs are used to test possible states within the probabilistic prediction and modeling system and evaluated by the best output function. An undo function can reverse the effect of applying a hypothetical output.

An injectable amino-acid composition acts naturally to fuel collagen synthesis, which retards aging and helps to clear cellular decay while accelerating the cell division that promotes healthy, younger looking skin. The amino-acid composition includes carnosine. The composition is injected into the dermis of patients. The composition can be used in conjunction with botulinum toxin and fillers to enhance their effectiveness and extend their usefulness.